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Abstract
Objective:  To  compare  the  prevalence  and  factors  associated  with  vertical  transmission  of
human immunodeﬁciency  virus  1  (HIV--1)  among  pregnant  women  treated  in  the  periods  of
1998--2004 and  2005--2011  in  a  reference  service  for  the  care  of  HIV-infected  patients  in  south-
ern Brazil.
Methods:  This  was  a  descriptive  and  analytical  study  that  used  the  databases  of  laboratories
from the  CD4  and  STDs/AIDS  Viral  Load  National  Laboratory  Network  of  the  Brazilian  Ministry
of Health.  HIV-1-infected  pregnant  women  were  selected  after  an  active  search  for  clinical
information  and  obstetric  and  neonatal  data  from  their  medical  records  between  the  years  of
1998 and  2011.
Results:  102  pregnant  women  were  analyzed  between  1998  and  2004  and  251  in  the  period
between 2005  and  2011,  totaling  353  children  born  to  pregnant  women  with  HIV-1.  It  was
observed that  the  vertical  transmission  rate  was  11.8%  between  1998  and  2004  and  3.2%  between
2005 and  2011  (p  <  0.001).  The  increased  use  of  antiretroviral  drugs  (p  =  0.02),  the  decrease  in
viral load  (p  <  0.001),  and  time  of  membrane  rupture  lower  than  4  h  (p  <  0.001)  were  associated
with the  decrease  of  vertical  transmission  factors  when  comparing  the  two  periods.
Conclusion:  It  was  observed  a  decrease  in  the  rate  of  vertical  transmission  in  recent  years.
According  to  the  studied  variables,  is  suggested  that  the  risk  factors  for  vertical  transmission
of HIV-1  were  absence  of  antiretroviral  therapy,  high  viral  load  in  the  pregnant  women,  and
membrane  rupture  time  >4  h.
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Avaliac¸ão  dos  fatores  associados  à  transmissão  vertical  de  HIV-1
Resumo
Objetivo:  Comparar  a  prevalência  e  os  fatores  associados  à  transmissão  vertical  de  HIV-1  entre
grávidas  tratadas  nos  períodos  de  1998-2004  e  2005-2011  em  um  servic¸o  de  referência  de
cuidado de  pacientes  com  HIV  no  sul  do  Brasil.
Métodos:  Estudo  descritivo  e  analítico  que  utilizou  as  bases  de  dados  de  laboratórios  da  Rede
Nacional de  Laboratórios  de  CD4  e  Carga  Viral  de  DSTs/AIDS  do  Ministério  da  Saúde.  As  grávidas
com HIV-1  foram  selecionadas  em  uma  pesquisa  ativa  de  informac¸ões  clínicas  e  dados  obstétricos
e neonatais  em  seus  prontuários  médicos  entre  1998-2011.
Resultados:  102  grávidas  foram  analisadas  entre  1998  e  2004  e  251  entre  2005-2011,  total-
izando 353  crianc¸as  nascidas  de  grávidas  com  HIV-1.  Observou-se  que  a  transmissão  vertical  foi
de 11,8%  entre  1998  e  2004  e  de  3,2%  entre  2005-2011  (p  <  0,001).  O  maior  uso  de  medicamentos
antirretrovirais  (p  =  0,02),  a  reduc¸ão  na  carga  viral  (p  <  0,001)  e  o  tempo  de  ruptura  de  mem-
branas menor  de  4  h  (p  <  0,001)  foram  associados  à  reduc¸ão  nos  fatores  de  transmissão  vertical
quando  os  dois  períodos  são  comparados.
Conclusão:  Observou-se  uma  reduc¸ão  na  taxa  de  transmissão  vertical  nos  últimos  anos.  De
acordo com  as  variáveis  estudadas,  sugere-se  que  os  fatores  de  risco  de  transmissão  vertical
de HIV-1  foram  ausência  de  terapia  antirretroviral,  alta  carga  viral  das  grávidas  e  tempo  de
ruptura maior  de  4  h.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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he  mother-to-child  transmission  (MTCT)  of  human  immu-
odeﬁciency  virus  type  1  (HIV-1)  can  occur  in  three  major
eriods:  in  utero, at  birth,  or  during  breastfeeding.1 HIV-
 can  be  transmitted  in  utero  via  transplacental  cellular
ransport,  through  a  progressive  infection  of  the  placenta’s
rophoblasts  until  the  virus  reaches  the  fetal  circulation
r  due  to  ruptures  in  the  placental  barrier  followed  by
icrotransfusions  that  occur  from  mother  to  child.2 The
ransmission  during  delivery  occurs  via  the  contact  of
he  fetus  with  infected  maternal  secretions  while  passing
hrough  the  birth  canal,  through  ascending  infection  from
agina  to  fetal  membranes  and  amniotic  ﬂuid  or  through
bsorption  in  the  neonatal  digestive  tract.  In  the  postpartum
eriod,  the  main  form  of  transmission  is  breastfeeding.3
The  vertical  transmission  route  of  HIV-1  can  be  inﬂuenced
y  several  factors,  such  as  the  delivery  mode,4 the  use  of
ntiretroviral  therapy,5 oral  inﬂammations  in  the  newborn,6
rematurity,  and  high  maternal  viral  load.7 In  addition  to
hese  factors,  the  viral  genetic  diversity  appears  to  play  an
mportant  role  in  vertical  transmission.1,8
The  epidemic  of  acquired  immunodeﬁciency  syndrome
AIDS)  is  in  process  of  stabilization;  however,  it  still  presents
igh  rates  of  transmission,  especially  among  women,  which
haracterizes  the  feminization  of  the  disease.9 Therefore,
t  is  important  to  understand  the  epidemiological  proﬁle  of
regnant  women  and  of  MTCT,  since  the  changes  in  preva-
ence  depend  on  factors  such  as  the  use  of  antiretrovirals
nd  the  adhesion  to  prenatal  care.  These  and  other  fac-
ors  may  lead  to  a  reduction  in  MTCT,  thereby  facilitating
he  adoption  of  more  effective  preventive  measures.9,10 In
razil,  from  1980  to  June  of  2013,  it  was  estimated  that
18,230  people  were  living  with  HIV/AIDS.11 According  to
M
T
nhe  Brazilian  epidemiological  bulletin  of  2013,  considered
nformation  from  2010,  the  prevalence  of  HIV  infection
n  pregnant  women  was  0.38%.11 Vertical  transmission  has
ecome  a  major  challenge  to  public  health,  as  epidemiolog-
cal  data  show  that  80%  of  HIV  cases  in  children  under  13
ears  had  MTCT  as  the  form  of  transmission.11
Due  to  the  increasing  number  of  infected  pregnant
omen,  actions  such  as  the  development  of  governmen-
al  programs  and  the  monitoring  of  pregnant  women  have
een  implemented  since  2000  in  Brazil;  healthcare  staff
ave  the  obligation  to  report  cases  of  infected  women  and
xposed  children.11 According  to  data  from  the  National  Dis-
ase  Notiﬁcation  System  (Sistema  de  Informac¸ão  de  Agravos
e  Notiﬁcac¸ão  [SINAN]),11 77,066  cases  of  HIV  in  pregnant
omen  were  reported  from  2000  to  2013;  The  South  region
f  Brazil  is  in  second  place  with  31.3%  of  cases,  behind  only
he  Southeast  region  (41.7%),  and  followed  by  the  North-
ast  (14.9%),  North  (6.3%),  and  Midwest  regions  (5.7%).  The
etection  rate  of  AIDS  in  children  under  5  years  (the  indica-
or  used  in  Brazil  to  monitor  the  vertical  transmission  of  HIV)
etween  2012  and  2003  presented  a  reduction  of  35.8%.11
This  study  aimed  to  compare  the  prevalence  and  fac-
ors  associated  with  vertical  transmission  of  HIV-1  among
omen  treated  from  1998  to  2004  and  from  2005  to  2011
n  a  reference  service  for  the  care  of  HIV-infected  patients
n  Southern  Brazil,  located  at  the  University  Hospital  of  the
ederal  University  of  Rio  Grande  (HU-FURG),  in  the  city  of
io  Grande,  RS,  Brazil.ethods
his  was  a  descriptive  and  analytic  study  that  included  102
ewborns  from  HIV-1  positive  pregnant  women  in  the  period
sion  525
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DEvaluation  of  factors  associated  with  vertical  HIV-1  transmis
1998--2004  and  251  in  the  period  2005--2011,  with  a  total  of
353  births.
Despite  the  fact  that  Brazilian  governmental  programs
and  monitoring  of  pregnant  women  were  implemented  in
2000,  the  care  for  HIV  patients  in  HU-FURG  began  in  1994,
with  testing  and  subsequent  observation  of  the  high  inci-
dence  of  cases  in  the  region.  Such  attention  was  ruled  from
normative  of  the  Brazilian  Ministry  of  Health  and  subse-
quently  every  care  protocols  met  as  such  recommendations.
Due  to  certain  changes,  such  as  the  higher  prevalence  of
viral  subtype  C  and  the  difference  of  the  therapeutic  and
pharmacological  model  of  the  patient  with  HIV  referenced
in  different  analyzed  periods,  it  was  decided  to  stratify  the
data  so  that  analysis  would  be  feasible.  Moreover,  it  could
report  the  effectiveness  of  care  models  recommended  by
Brazilian  Ministry  of  Health.8,12
Since  1998,  all  pregnant  women  attended  to  at  HU-
FURG  were  subjected  to  HIV/AIDS  tests  as  recommended  in
the  guidelines  by  the  Brazilian  Ministry  of  Health.  Pregnant
women  who  presented  two  positive  serologic  tests  and  one
conﬁrmation  test,  or  two  consecutives  tests  with  detectable
viral  load,  were  classiﬁed  as  HIV-infected.  The  mothers
signed  an  informed  consent  to  participate  in  this  research,
which  was  approved  by  the  research  ethics  committee  of
the  institution  (Protocol  No.  23116001368/2003-44).
The  study  outcome  was  MTCT  of  HIV-1  in  newborns,  and
the  studied  variables  were:  use  of  highly-active  antiretro-
viral  therapy  (HAART)  -- Biovir® (lamivudina  + zidovudina,
GlaxoSmithKline  Brasil,  RJ,  Brazil)  +  Kaletra® (Lopinavir  e
Ritonavir,  Abbot,  USA)  during  pregnancy,  CD4+ T  cells  count
in  the  last  three  months  of  pregnancy,  pregnant  women  viral
load,  delivery  mode,  membrane  rupture  time,  and  birth-
weight  (kg).  The  use  of  antiretroviral  therapy  was  classiﬁed
as:  a)  complete,  --  when  the  mother  received  antiretrovirals
during  pregnancy  and  in  the  moment  of  delivery  as  well  as
the  newborn;  and  b)  incomplete,  when  at  least  one  of  the
three  procedures  were  conducted  or  when  the  mother  did
not  use  antiretroviral  therapy.  Socio-demographic  variables
were  not  standardized  between  these  periods.  Therefore,  it
was  not  possible  to  describe  the  demographic  proﬁle  of  the
population  in  this  study.
Data  was  analyzed  using  Stata  version  8.0  (StataCorp  --
College  Station,  TX,  USA).  An  analytical  descriptive  analy-
sis  of  numerical  variables  was  performed  according  to  the
studied  periods,  which  were  presented  by  their  frequencies,
mean  values,  standard  deviation,  and  a  signiﬁcant  p-value
of  0.05  in  a  two-tailed  test.
Results
This  study  assessed  353  children  born  from  HIV-1  positive
pregnant  women,  attended  to  at  HU-FURG.
This  study  showed  that  the  rates  of  mother-to-child
transmission  obtained  between  1998  and  2004  and  between
2005  and  2011  decreased  signiﬁcantly  (p  <  0.001),  from
11.8%  to  3.2%,  respectively.  It  id  interesting  to  observe  the
results  in  different  periods:  the  transmission  rate  from  1998
to  2000  was  11.8%;  from  2001  to  2004,  the  rate  was  7.7%;
from  2005  to  2008,  2.7%;  and  from  2009  to  2011  the  trans-
mission  rate  was  2.9%  (Fig.  1).
B
t
tigure  1  Comparison  of  the  mother-to-child  HIV-1  transmis-
ion rates  from  1998  to  2011  in  a  reference  service.
For  the  analyzed  variables  in  both  studied  periods
Table  1),  it  was  observed  that  between  the  periods  from
998  to  2004,  79.4%  of  the  pregnant  women  had  a  membrane
upture  time  longer  than  4  h.  In  contrast,  for  the  period
etween  2005  and  2011,  only  10.8%  of  pregnant  women  had
 membrane  rupture  time  longer  than  4  h  (p  <  0.001).
There  was  no  signiﬁcant  difference  in  the  mode  of  deliv-
ry  between  the  two  studied  periods,  nor  in  the  average
irthweight.  The  use  of  antiretroviral  therapy  throughout
he  gestational  period  was  observed  in  69.7%  of  the  pregnant
omen.  Between  1998  and  2004,  60.7%  of  pregnant  women
dhered  to  HAART  and,  between  the  years  2005  and  2011,
he  adhesion  rate  was  73.3%  (p  <  0.02),  suggesting  that  adhe-
ion  to  the  antiretroviral  therapy  by  pregnant  women  is  an
mportant  factor  in  the  reduction  of  MTCT.  It  was  consid-
red  complete  use  of  antiretroviral  therapy  when  mothers
eported  having  used  the  drug  during  the  antenatal  period,
t  delivery  and  her  newborn  have  received  prophylaxis  with
ral  suspension  of  zidovudine  (AZT)  for  six  weeks  after  deliv-
ry.  The  use  of  injectable  AZT  and  oral  AZT  was  checked  with
he  drug  dispensing  control  spreadsheets  during  hospitaliza-
ions,  according  to  the  protocol  established  by  the  Brazilian
inistry  of  Health.  Since  1998,  PMTCT  attention  was  per-
ormed  following  the  recommendation  to  AZT  monotherapy.
n  2001,  triple  therapy  was  recommended,  inserting  Biovir®
nd  Nelﬁnavir.  In  2007,  following  a  recommendation  of
he  Brazilian  Ministry  of  Health,  Kaletra® was  introduced,
eplacing  Nelﬁnavir.
There  was  an  increase  in  the  CD4+ T  cells  count  (CD4+
 cells  >  500)  when  comparing  both  studied  periods.  In  the
eriod  from  1998  to  2004,  28.4%  of  pregnant  women  pre-
ented  CD4+ T  cells  count  higher  than  500.  In  the  period  from
005  to  2011,  the  percentage  of  pregnant  women  with  CD4+
 cells  count  higher  than  500  increased  to  57.3%  (p  < 0.001).
When  analyzing  the  maternal  viral  load,  it  was  observed
hat  the  percentage  of  pregnant  women  with  viral  load
etween  undetectable  and  log  of  2.9  was  68.0%  in  the  period
rom  2005  to  2011  and  28.4%  in  the  period  from  1998  to  2004
p  <  0.001).
iscussionrazil  aims  to  eliminate  HIV-1  vertical  transmission  (less
han  1%  of  transmission)  until  2015.11 Studies  have  shown
hat  it  is  possible  to  prevent  new  HIV  infection  in  children
526  da  Rosa  MC  et  al.
Table  1  Comparison  of  factors  associated  with  mother-to-child  HIV-1  transmission  between  the  periods  1998  and  2004  and
2005--2011 in  a  reference  service.
Membrane  rupture  time  p-value
Period n  >4  h  %  <4  h  %  <0.001
1998--2004  102  81  79.4  21  20.6
2005--2011 251  27  10.8  224  89.2
Total 353  108  30.6  245  69.4
Delivery  mode  0.67
n  Cesarean  %  Normal  %
1998--2004  102  39  38.2  63  61.7
2005--2011  251  90  35.8  161  64.8
Total 353  129  36.5  224  63.5
Mother-to-child  transmission  <0.001
n  HIV+  %  HIV−  %
1998--2004 102  12  11.8  90  88.2
2005--2011 251  8  3.2 243  96.8
Total 353 20  5.7 333  94.3
Antiretroviral  therapy  during  pregnancy  0.02
n  Incomplete  %  Complete  %
1998--2004 102  40  39.3 62  60.7
2005--2011 251  67  26.7  184  73.3
Total 353 107  30.3  246  69.7
T CD4+  cell  count
n  cell  0--199  %  cell  200--499  %  Cell  >  500  %
1998--2004 95  18  18.9  50  52.6  27  28.4
2005--2011 251  13  5.2  94  37.5  144  57.3
p <0.001 <0.001 1.00
Maternal  viral  load  --  Log10
n  0--2.99  %  3.0--3.99  %  4.0--4.99  %  ≥5  %
1998--2004  95  27  28.4  23  24.2  35  36.8  10  10.5
2005--2011 251  173  68.9  49  19.5  26  10.3  3  1.2
p <0.001  0.37  <0.001  <0.001
Newborn  gender  0.68
n  Male  %  Female  %
1998--2004  102  54  52.9  48  47.1
2005--2011  251  127  50.5  124  49.5
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hen  HIV-positive  pregnant  women  have  timely  and  appro-
riate  access  to  prenatal  care  and  to  HAART.13 In  the  present
tudy,  a  5.7%  rate  of  vertical  transmission  was  observed  from
 total  of  353  children  born  from  seropositive  mothers  for
IV-1  between  the  years  1998  and  2011.  However,  it  is  inter-
sting  to  analyze  the  rate  of  MCTC  in  different  periods.  In
his  study,  between  1998  and  2000,  the  MTCT  rate  was  11.8%;
rom  2001  to  2004,  7.7%;  from  2005  to  2008,  2.7%;  and  from
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009  to  2011,  2.9%.  This  demonstrates  that  the  MTCT  rates
re  relatively  lower  when  analyzed  at  different  times.  There
as  a  small  increase  in  MTCT  rates  between  the  years  2005
nd  2008  (2.7%)  and  2009--2011(2.9%),  which  may  be  justi-
ed  due  to  the  fact  that  a  portion  of  HIV-positive  pregnant
omen  still  do  not  make  use  of  chemoprophylaxis  during
he  pregnancy,  especially  drug  users  and  currently  the  use
f  crack  cocaine.  Data  showed  that  pharmacy  records  can
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help  identify  less-than-optimal  adherence  to  treatment.14
Given  the  stabilization  of  MTCT  rates  observed  not  only  in
this  study,  but  throughout  in  Brazil,  the  Brazilian  Ministry
of  Health  implemented  in  2012  the  use  of  nevirapine  (NVP;
Technical  Note  n.  388/2012).  In  Brazil,  the  use  of  AZT  asso-
ciated  with  NPV  has  been  advocated  for  the  prevention  of
MTCT,  since  a  recently  published  study  demonstrated  that
the  oral  treatment  with  a  solution  containing  AZT  during
six  months  associated  to  an  oral  suspension  with  NPV  (three
doses  in  the  ﬁrst  week  of  life)  signiﬁcantly  reduces  the  rate
of  MTCT  from  pregnant  women  who  did  not  use  chemopro-
phylaxis  during  pregnancy.11
Taking  into  account  the  aim  of  this  study,  observing  the
rates  obtained  between  1998  and  2004  and  2005--2011,  a  sig-
niﬁcant  drop  in  the  transmission  rates  (from  11.8%  to  3.2%,
respectively)  was  observed,  clearly  demonstrating  a  reduc-
tion  in  MTCT  rates.  Comparing  these  results  with  studies
conducted  in  the  same  Brazilian  region,  a  studied  published
in  2006  observed  a  MTCT  rate  of  11.8%  in  infants  born
between  1998  and  2003.12 In  another  study  published  in  2010
from  the  same  region,  a  MTCT  rate  of  4.8%  was  observed
between  the  years  2003  and  2007.8 In  the  present  study,  the
MTCT  rate  was  only  2.9%  when  considering  only  the  period
from  2007  to  2011.  These  results  clearly  demonstrate  that
there  has  been  a  decrease  in  the  MTCT  rates  of  HIV-1,  which
highlights  the  effectiveness  of  the  national  policy  for  the
control  of  MTCT.
With  the  approval  of  Law  No.  9313,  on  November  13,
1996,  Brazil  began  to  rely  in  its  legal  system  with  a  legis-
lation  that  ensures  the  access  to  antiretroviral  medication
for  individuals  living  with  HIV/AIDS.  Thus,  Brazil  became
the  ﬁrst  emerging  country  to  provide  antiretroviral  ther-
apy.  In  2009,  the  Secretary  of  Substitute  Health  Surveillance
started  to  use  fast  HIV  tests  in  pregnant  women,  accord-
ing  to  the  authority  conferred  by  the  Article  45  of  the
Decree  No.  6860  of  May  27,  20099,11 Therefore,  it  can
be  suggested  that  these  control  measures  had  an  inﬂu-
ence  in  the  decline  of  the  HIV  infection  rates  in  infants
between  the  studied  periods,  demonstrating  the  importance
of  these  control  measures  in  public  healthcare  services.
Similar  decreases  in  MTCT  rates  were  observed  in  several
countries  that  adopted  control  measures,  especially  the  use
of  antiretroviral  therapy  by  HIV-positive  pregnant  women.15
In  the  present  study,  it  was  observed  that  69.7%  of  moth-
ers  made  use  of  antiretroviral  medication  throughout  the
gestational  period,  suggesting  a  decline  in  the  vertical  trans-
mission  rate.  In  a  study  published  in  2011,  it  was  observed
that,  from  25  seropositive  children,  9%  were  born  from
mothers  who  received  inadequate  antiretroviral  therapy
during  pregnancy,  a  fact  that  occasioned  a  rate  of  only  1.7%
of  vertical  transmission.16
When  analyzing  the  different  periods  of  this  study,  it  was
observed  that,  between  1998  and  2004,  60.7%  of  pregnant
women  adhered  to  antiretroviral  therapy  and,  between
2005  and  2011,  there  was  an  increase  in  this  adherence:
73.3%.  This  suggests  a  low  viral  load  in  pregnant  women
and  a  decrease  in  vertical  transmission  rates  between  the
periods  from  2005  to  2011,  only  3.2%.  These  results  corrob-
orate  those  from  a  previous  study,  which  demonstrated  that
the  main  risk  factors  for  HIV  transmission  were  failure  of
antiretroviral  therapy,  late  maternal  diagnosis  and,  conse-
quently,  high  viral  load  of  pregnant  women  at  delivery.8 The
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se  of  antiretroviral  therapy  during  pregnancy  is  extremely
mportant  in  order  to  prevent  vertical  transmission;  it  can  be
sed  during  any  period,  regardless  of  the  clinical  condition
f  the  mother.17 Studies  have  reported  that  a  high  viral  load
nd  a  low  CD4+ T cells  count  during  pregnancy  are  signiﬁcant
actors  in  MTCT.8,18
It  is  noteworthy  that  a  membrane  rupture  time  lower
han  4  h  is  extremely  important  to  reduce  MTCT.19 In  the
resent  study,  observed  a  signiﬁcant  decrease  (p  <  0.001)
n  rupture  time  was  observed  when  analyzing  the  stud-
ed  periods,  since  79.4%  of  pregnant  women  had  a  rupture
ime  higher  than  4  h  in  the  period  from  1998  to  2004.  In
ontrast,  from  2005  to  2011,  this  rate  was  10.8%.  The  signif-
cant  difference  between  membrane  rupture  time  in  both
tudied  periods  is  the  result  of  the  update  of  care  proto-
ols  for  HIV-infected  pregnant  women.  In  2004,  HIV  testing
uring  prenatal  care  and  proper  implementation  of  preven-
ion  actions  of  vertical  transmission  of  HIV  were  initiated,
nd  the  ﬁrst  protocol  was  published  in  2007.  According  to
he  Brazilian  guideline  for  prophylaxis  of  HIV  transmission
nd  antiretroviral  therapy  in  pregnant  women,  the  active
anagement  of  labor  should  occur  to  prevent  prolonged
embrane  rupture  time,  since  a  reduced  time  decreases
he  risk  of  vertical  transmission.9
Despite  of  the  effort  to  reduce  MTCT,  the  residual  risk
f  that  transmission  is  still  relatively  high  in  comparison  of
hat  it  is  observed  in  countries  who  adopt  HAART.20 The  fact
hat  Southern  Brazil  is  characterized  by  having  a  highere
revalence  of  HIV-1  subtype  C,  which  is  more  transmissible
n  utero,8 may  explain  the  rate  of  MTCT  found  in  the  present
tudy.  Additionally,  late  entrance  and  lack  of  adherence  to
renatal  care,  especially  in  drug  users,  favor  MTCT.  A  study
emonstrated  that  low  prenatal  screening  of  maternal  HIV
nfection,  impairing  maternal  treatment  or  prophylaxis,  and
he  incorrect  use  of  the  rapid  screening  test  at  admission
or  delivery  are  impediments  to  the  effective  reduction  of
TCT.21 Aiming  to  increase  the  care  for  pregnant  women
ith  low  adherence  to  prenatal,  especially  those  drug  users,
he  referral  service  of  HU-FURG  conducts  active  search  of
omen  in  favor  of  the  effectiveness  of  compliance  with  care
rotocols  to  prenatal  care  as  recommended  by  the  Brazilian
inistry  of  Health.
Therefore,  the  results  of  the  present  study  suggest  that
he  increase  of  antiretroviral  therapy  during  pregnancy,  time
or  membrane  rupture  lower  than  4  h,  and  low  viral  load
ontributed  to  the  decline  MTCT  in  both  studied  periods.
hese  results  are  in  agreement  with  the  data  obtained  in  the
iterature.2,7,22 However,  more  studies  should  be  conducted
o  establish  which  factors  are  involved  in  MTCT.
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